Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Plasma interferon-gamma-inducible protein 10 can be used to predict viral load in HIV-1-infected individuals.

Gray CM, Hong HA, Young K, Lewis DA, Fallows D, Manca C, Kaplan G.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):e115-6. doi: 10.1097/QAI.0b013e3182930ea8. No abstract available.

2.

Interferon-inducible protein 10 (IP-10) is associated with viremia of early HIV-1 infection in Korean patients.

Lee S, Chung YS, Yoon CH, Shin Y, Kim S, Choi BS, Kim SS.

J Med Virol. 2015 May;87(5):782-9. doi: 10.1002/jmv.24026. Epub 2015 Feb 10.

PMID:
25678246
3.

Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection.

Liovat AS, Rey-Cuillé MA, Lécuroux C, Jacquelin B, Girault I, Petitjean G, Zitoun Y, Venet A, Barré-Sinoussi F, Lebon P, Meyer L, Sinet M, Müller-Trutwin M.

PLoS One. 2012;7(10):e46143. doi: 10.1371/journal.pone.0046143. Epub 2012 Oct 2.

4.

Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1.

Vargas A, Berenguer J, Ryan P, Catalán P, López JC, Cosín J, Miralles P, Resino S.

J Acquir Immune Defic Syndr. 2010 Jun;54(2):219-20. doi: 10.1097/QAI.0b013e3181d01d05. No abstract available.

PMID:
20505475
5.

Genital Inflammation Predicts HIV-1 Shedding Independent of Plasma Viral Load and Systemic Inflammation.

Blish CA, McClelland RS, Richardson BA, Jaoko W, Mandaliya K, Baeten JM, Overbaugh J.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):436-40. doi: 10.1097/QAI.0b013e31826c2edd.

6.

Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.

Messele T, Brouwer M, Girma M, Fontanet AL, Miedema F, Hamann D, Rinke de Wit TF.

Clin Immunol. 2001 Feb;98(2):212-9.

PMID:
11161977
7.
8.

Increased plasma CXCL10 may be a marker of increased risk of immune restoration disease associated with nonviral pathogens.

Oliver BG, Price P, Wand H, French MA.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):e47-9. doi: 10.1097/QAI.0b013e3182427796. No abstract available.

PMID:
22327247
9.

Viral load versus p24 antigenaemia in human immunodeficiency virus infected patients.

Eiros JM, Hernández B, Ortega M, de Lejarazu RO.

Br J Biomed Sci. 2001;58(4):246-7. No abstract available.

PMID:
11788003
10.

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.

Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.

PMID:
23274935
11.

Usefulness of alternate prognostic serum and plasma markers for antiretroviral therapy for human immunodeficiency virus type 1 infection.

Kannangai R, Kandathil AJ, Ebenezer DL, Mathai E, Prakash AJ, Abraham OC, Sudarsanam TD, Pulimood SA, Selvakumar R, Job V, Sridharan G.

Clin Vaccine Immunol. 2008 Jan;15(1):154-8. Epub 2007 Nov 14.

12.

HIV-1 load quantitation: a 17-year perspective.

Holodniy M.

J Infect Dis. 2006 Sep 15;194 Suppl 1:S38-44. Review.

PMID:
16921471
13.

Advances in HIV markers.

Elliott EB.

Can Fam Physician. 1996 Nov;42:2301-2. No abstract available.

14.

Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.

Sisay Z, Berhe N, Petros B, Tegbaru B, Messele T, Hailu A, Wolday D.

Ethiop Med J. 2011 Jul;49(3):179-86.

PMID:
21991751
15.

Use of virologic markers in clinical practice.

Saag MS.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16 Suppl 1:S3-13. Review.

PMID:
9389310
16.

Immune activation and plasma viral load in HIV-infected African individuals.

Dyer JR, Hoffman IF, Eron JJ Jr, Fiscus SA, Cohen MS.

AIDS. 1999 Jul 9;13(10):1283-5. No abstract available.

PMID:
10416540
17.

Longitudinal changes in HIV-1-specific T-cell quality associated with viral load dynamic.

Dembek CJ, Kutscher S, Allgayer S, Russo C, Bauer T, Hoffmann D, Goebel FD, Bogner JR, Erfle V, Protzer U, Cosma A.

J Clin Virol. 2012 Oct;55(2):114-20. doi: 10.1016/j.jcv.2012.06.017. Epub 2012 Jul 13.

PMID:
22795599
19.

Estimation of virological and immunological parameters in subjects from South India infected with human immunodeficiency virus type 1 clade C and correlation of findings with occurrence of neurological disease.

Kamat A, Ravi V, Desai A, Satishchandra P, Satish KS, Kumar M.

J Neurovirol. 2009 Jan;15(1):25-35. doi: 10.1080/13550280802338652. Epub 2008 Nov 22.

PMID:
19031329
20.

[The prognostic value of virology and immunology markers in Chinese HIV-1 infected people].

Lin X, Xu L, Shao Y.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1999 Mar;13(1):41-4. Chinese.

PMID:
12759951

Supplemental Content

Support Center